When funding is tight, life sciences startups must be even more strategic with requested amounts, timing, and funding sources ...

Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's ...

Leadership in pharma means questioning assumptions, amplifying diverse voices, and creating environments where authenticity ...

Building iteration into the product commercialization process can help life sciences companies avoid many of the missteps ...

Medical affairs can no longer afford to operate within legacy structures. Enter AI-enabled functional service provider (FSP) models that offer operational relief.

Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

Artificial intelligence is revolutionizing the life sciences industry by driving innovation in various domains, such as drug discovery, clinical trials, and regulatory compliance. While AI offers the ...